-
公开(公告)号：US20230136218A1
公开(公告)日：2023-05-04
申请号：US17762036
申请日：2020-09-23
发明人： Nick Van Gastel , David T. Scadden
IPC分类号： A61K31/47 , A61P35/02 , A61K31/7068 , A61K45/06 , A61K31/704
摘要： The disclosure relates to compositions, methods, and kits for treating leukemia, specifically acute myeloid leukemia, in a subject.
-
公开(公告)号：US20210177880A1
公开(公告)日：2021-06-17
申请号：US16760901
申请日：2018-10-31
IPC分类号： A61K31/7048
摘要： The disclosure relates to compositions, methods, and kits for treating leukemia, specifically acute myeloid leukemia, in a subject, and for detecting chemoresistant acute myeloid leukemic cells.
-
公开(公告)号：US20180186879A1
公开(公告)日：2018-07-05
申请号：US15740619
申请日：2016-06-29
CPC分类号： C07K16/2803 , A61K9/0019 , A61K35/14 , A61K35/28 , A61K35/50 , A61K35/51 , A61K39/395 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/74 , C07K2317/76 , C12N5/0647
摘要： Disclosed herein are methods for enhancing hematopoietic reconstitution of a subject. One method involves administering a therapeutically effective amount of an inhibitor of Embigin to a recipient subject and can also optionally include administering hematopoietic stem/progenitor cells to the subject. Another method involves administering an inhibitor of Embigin to a donor prior to harvest of hematopoietic stem/progenitor cells. Pharmaceutical compositions relating to the methods are also described.
-
公开(公告)号：US20130338092A1
公开(公告)日：2013-12-19
申请号：US13969213
申请日：2013-08-16
申请人： The Broad Institute, Inc. , The General Hospital Corporation , Dana-Farber Cancer Institute, Inc. , The Brigham and Women's Hospital, Inc. , President and Fellows of Harvard College , Sloan-Kettering Institute for Cancer Research
发明人： Kimberly Hartwell , Malcolm A.S. Moore , David T. Scadden , Stuart L. Schreiber , Todd R. Golub , Benito Munoz , Benjamin L. Ebert , Andrew M. Stern , Peter G. Miller , D. Gary Gilliland , Anne Van Dyk Carpenter , David J. Logan , Joseph Negri , Nicola Tolliday , Alykhan Shamji , Siddhartha Mukherjee , Alison Stewart
IPC分类号： G01N33/50 , A61K31/4184 , A61K31/395 , A61K31/428 , A61K31/423 , A61K31/704 , A61K31/4745 , A61K31/405 , A61K31/4418 , A61K31/366 , A61K31/22 , A61K31/167 , A61K31/444
CPC分类号： G01N33/5011 , A61K31/167 , A61K31/22 , A61K31/366 , A61K31/395 , A61K31/405 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4418 , A61K31/444 , A61K31/4745 , A61K31/704 , A61K45/06
摘要： This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia.
摘要翻译： 本发明涉及用于鉴定有效靶向白血病干细胞的化合物的高通量半自动化方法，以及通过这些方法鉴定的化合物及其用于治疗白血病的用途。
-
公开(公告)号：US20210388094A1
公开(公告)日：2021-12-16
申请号：US17137337
申请日：2020-12-29
申请人： President and Fellows of Harvard College , The General Hospital Corporation , The Children's Medical Center Corporation
IPC分类号： C07K16/28 , C07K4/04 , A61K35/28 , A61K38/16 , G01N33/50 , A61K47/68 , G01N33/569 , G01N33/574
摘要： Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods.
-
公开(公告)号：US11116819B2
公开(公告)日：2021-09-14
申请号：US14771280
申请日：2014-02-28
IPC分类号： A61K31/727 , A61K35/28 , A61K38/19 , A61K38/20 , A61K39/395 , C12N5/0789 , C12N15/113 , C12N15/115 , A61K45/06 , A61K31/395 , A61K38/17 , G01N33/50 , C12N5/0775 , A61K36/00 , A61K35/12 , A61K39/00
摘要： The present invention relates to methods and compositions for mobilizing hematopoietic stem cells and/or progenitor cells, and related methods of conditioning for engraftment of transplanted hematopoietic stem cells and/or progenitor cells, and methods of treating diseases requiring hematopoietic stem cell and/or progenitor cell transplantation.
-
公开(公告)号：US10906980B2
公开(公告)日：2021-02-02
申请号：US16726803
申请日：2019-12-24
申请人： President and Fellows of Harvard College , The General Hospital Corporation , The Children's Medical Center Corporation
IPC分类号： A61K38/36 , A61K39/385 , C07K4/04 , C07K16/28 , A61K35/28 , A61K38/16 , G01N33/50 , A61K47/68 , G01N33/569 , G01N33/574
摘要： Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods.
-
公开(公告)号：US20200268850A1
公开(公告)日：2020-08-27
申请号：US16849950
申请日：2020-04-15
IPC分类号： A61K38/19 , A61K45/06 , A61K35/28 , A61K31/395 , A61K31/727 , A61K38/20 , A61K38/17 , G01N33/50
摘要： The present invention relates to methods and compositions for mobilizing hematopoietic stem cells and/or progenitor cells, and related methods of conditioning for engraftment of transplanted hematopoietic stem cells and/or progenitor cells, and methods of treating diseases requiring hematopoietic stem cell and/or progenitor cell transplantation.
-
公开(公告)号：US20200208114A1
公开(公告)日：2020-07-02
申请号：US16709710
申请日：2019-12-10
申请人： The Broad Institute, Inc. , Massachusetts Institute of Technology , The General Hospital Corporation , President and Fellows of Harvard College
IPC分类号： C12N5/0775 , G01N33/50 , C12N15/11 , C12N9/22 , A61K35/28 , C12Q1/6886
摘要： Described herein are signatures that characterize a particular stromal cell state, type, and/or subtype. In some embodiments, the signatures can characterize a dysfunctional stromal cell. In some embodiments, the signatures can be used to diagnose, treat, and/or prevent a disease. In some embodiments, the signatures can characterize remodeling in a bone marrow microenvironment. Also described herein are cell populations having a specific signature and modulated cells that can be modulate to have a specific signature.
-
公开(公告)号：US20190060525A1
公开(公告)日：2019-02-28
申请号：US16075937
申请日：2017-02-06
发明人： Nisarg J. Shah , Ting-Yu Shih , Angelo Mao , David J. Mooney , David T. Scadden
摘要： Disclosed are compositions and related methods of recapitulating bone marrow stroma using scaffold materials (e.g., a porous alginate hydrogel scaffold) containing one or more cellular differentiation factors, and one or more growth factors. Such methods and compositions promote the formation of an ectopic nodule or site that can improve transplanted cell engraftment and selectively drive the development of lymphocytes and the reconstitution of the adaptive immunity after hematopoietic stem cell transplant.
-
-
-
-
-
-
-
-
-
搜索结果
33 条记录 (耗时 0.028 秒)
